Soligenix (NASDAQ:SNGX – Get Free Report) posted its quarterly earnings data on Friday. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.04, Zacks reports.
Soligenix Price Performance
Shares of NASDAQ SNGX traded up $0.01 during mid-day trading on Friday, hitting $0.39. The company had a trading volume of 130,758 shares, compared to its average volume of 304,500. The business’s 50-day simple moving average is $0.41 and its 200-day simple moving average is $0.81. Soligenix has a 12 month low of $0.28 and a 12 month high of $6.23. The firm has a market cap of $5.81 million, a P/E ratio of -0.23 and a beta of 1.93.
Analyst Ratings Changes
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Soligenix in a research report on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has an average rating of “Sell”.
Institutional Trading of Soligenix
Institutional investors and hedge funds have recently modified their holdings of the company. XTX Topco Ltd acquired a new stake in Soligenix during the fourth quarter worth $37,000. StoneX Group Inc. acquired a new stake in shares of Soligenix during the 4th quarter valued at about $50,000. Jane Street Group LLC acquired a new position in Soligenix in the fourth quarter worth about $51,000. Banco BTG Pactual S.A. bought a new position in Soligenix during the third quarter worth about $54,000. Finally, Virtu Financial LLC bought a new stake in shares of Soligenix in the 3rd quarter valued at approximately $59,000. 3.60% of the stock is currently owned by institutional investors.
Soligenix Company Profile
Soligenix, Inc is a clinical?stage biopharmaceutical company focused on developing vaccines and therapeutics to address unmet medical needs in rare diseases and biodefense. The company leverages proprietary technologies to create novel vaccine adjuvants, small?molecule innate defense regulators and photodynamic therapies aimed at improving patient outcomes in orphan indications and protecting public health against biological threats.
The company’s pipeline is organized into two core divisions.
See Also
- Five stocks we like better than Soligenix
- Axon’s Post-Earnings Pullback May Be More About Valuation Than Growth
- Uber Stock Lags in 2026, But Cash Flow and AV Bets Fuel Upside
- AppLovin Stock Hits 52-Week Low as Analysts Trim Targets, Stay Bullish
- Why These 3 Equal Weight ETFs Have Outperformed the S&P This Year
Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with MarketBeat.com's FREE daily email newsletter.
